trelagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 5013 865759-25-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • TAK-472
  • trelagliptin
  • trelagliptin succinate
  • SYR-472
  • SYR111472
  • zafatek
Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan for the treatment of type 2 diabetes mellitus.
  • Molecular weight: 357.39
  • Formula: C18H20FN5O2
  • CLOGP: 1.41
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 93.67
  • ALOGS: -3.22
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2015 PMDA Takeda

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.4 Basic
pKa2 1.33 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 8.40 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
Q836OWG55H UNII
D10178 KEGG_DRUG
1029877-94-8 SECONDARY_CAS_RN
C4045234 UMLSCUI
CHEBI:134715 CHEBI
6RL PDB_CHEM_ID
CHEMBL1650443 ChEMBL_ID
15983988 PUBCHEM_CID
DB15323 DRUGBANK_ID
CHEMBL2105754 ChEMBL_ID
9556 INN_ID
C000595449 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None